Daud A - Search Results

1

The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.

Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, Shevde LA, Li W, Eschrich S, Daud A, Ju J, Matta J. Riker AI, et al. Among authors: daud a. BMC Med Genomics. 2008 Apr 28;1:13. doi: 10.1186/1755-8794-1-13. BMC Med Genomics. 2008. PMID: 18442402 Free PMC article.

2

Immunotherapy as part of a multidisciplinary approach to melanoma treatment.

Riker AI, Jove R, Daud AI. Riker AI, et al. Front Biosci. 2006 Jan 1;11:1-14. doi: 10.2741/1775. Front Biosci. 2006. PMID: 16146709 Review.

3

Activated stat-3 in melanoma.

Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI. Messina JL, et al. Cancer Control. 2008 Jul;15(3):196-201. doi: 10.1177/107327480801500302. Cancer Control. 2008. PMID: 18596671 Free article.

4

Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma.

Jensen EH, Lewis JM, McLoughlin JM, Alvarado MD, Daud A, Messina J, Enkemann S, Yeatman TJ, Sondak VK, Riker AI. Jensen EH, et al. Among authors: daud a. Ann Surg Oncol. 2007 Apr;14(4):1416-23. doi: 10.1245/s10434-006-9226-2. Epub 2006 Dec 30. Ann Surg Oncol. 2007. PMID: 17195911

5

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.

Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. Daud AI, et al. J Clin Oncol. 2008 Dec 20;26(36):5896-903. doi: 10.1200/JCO.2007.15.6794. Epub 2008 Nov 24. J Clin Oncol. 2008. PMID: 19029422 Free PMC article. Clinical Trial.

6

Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.

Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, Lee JH, Sondak VK, Riker AI, Deconti RC, Gabrilovich D. Daud AI, et al. J Clin Oncol. 2008 Jul 1;26(19):3235-41. doi: 10.1200/JCO.2007.13.9048. J Clin Oncol. 2008. PMID: 18591558 Clinical Trial.

7

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Nghiem P, et al. Among authors: daud a. J Clin Oncol. 2019 Mar 20;37(9):693-702. doi: 10.1200/JCO.18.01896. Epub 2019 Feb 6. J Clin Oncol. 2019. PMID: 30726175 Free PMC article. Clinical Trial.

8

Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.

Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H. Niu G, et al. Among authors: daud a. Oncogene. 2002 Oct 10;21(46):7001-10. doi: 10.1038/sj.onc.1205859. Oncogene. 2002. PMID: 12370822

9

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.

Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Marchion DC, et al. Cancer Res. 2005 May 1;65(9):3815-22. doi: 10.1158/0008-5472.CAN-04-2478. Cancer Res. 2005. PMID: 15867379

10

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.

Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Marchion DC, et al. Mol Cancer Ther. 2005 Dec;4(12):1993-2000. doi: 10.1158/1535-7163.MCT-05-0194. Mol Cancer Ther. 2005. PMID: 16373714

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

399 results

Search Page